Treatment strategies for allergy and asthma

Nature Reviews Immunology

Volumn 8, Issue 3, 2008, Pages 218-230

  Holgate, Stephen T ^a   Polosa, Riccardo ^b  

^a SOUTHAMPTON GENERAL HOSPITAL   (United Kingdom)

^b UNIVERSITY OF CATANIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIALLERGIC AGENT; ANTIASTHMATIC AGENT; CYTOKINE; CYTOKINE RECEPTOR; EOTAXIN 2; EOTAXIN 3; GAMMA INTERFERON; GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; IMMUNOGLOBULIN E; INTERCELLULAR ADHESION MOLECULE 1; INTERLEUKIN 10; INTERLEUKIN 13; INTERLEUKIN 17; INTERLEUKIN 1BETA; INTERLEUKIN 2 RECEPTOR; INTERLEUKIN 3; INTERLEUKIN 4; INTERLEUKIN 5; INTERLEUKIN 8; INTERLEUKIN 9; MACROPHAGE INFLAMMATORY PROTEIN 1ALPHA; MONOCYTE CHEMOTACTIC PROTEIN 1; MONOCYTE CHEMOTACTIC PROTEIN 2; MONOCYTE CHEMOTACTIC PROTEIN 3; MONOCYTE CHEMOTACTIC PROTEIN 4; RANTES; THYMUS AND ACTIVATION REGULATED CHEMOKINE; TRANSCRIPTION FACTOR FOXP3; UNINDEXED DRUG; VASCULAR CELL ADHESION MOLECULE 1;

ALLERGY; ASTHMA; CELL ACTIVATION; CELL POLARITY; DRUG RESEARCH; EPIDEMIC; HUMAN; IMMUNOTHERAPY; MEDIATOR RELEASE; NONHUMAN; PRIORITY JOURNAL; REVIEW; SIGNAL TRANSDUCTION; TH2 CELL; TREATMENT PLANNING;

ANIMALS; ASTHMA; DESENSITIZATION, IMMUNOLOGIC; DRUG DELIVERY SYSTEMS; HUMANS; HYPERSENSITIVITY; VACCINES, SYNTHETIC;

EID: 40049092917     PISSN: 14741733     EISSN: None     Source Type: Journal    
DOI: 10.1038/nri2262     Document Type: Review

References (174)

1. Georas, S. N., Guo, J., De, F. U. & Casolaro, V. T-helper cell type-2 regulation in allergic disease. Eur. Respir. J. 26, 1119-1137 (2005).
2. Sicherer, S. H. & Sampson, H. A. Peanut allergy: emerging concepts and approaches for an apparent epidemic. J. Allergy Clin. Immunol. 120, 491-503 (2007).
3. Asher, M. I. et al. Worldwide time trends in the prevalence of symptoms of asthma, allergic rhinoconjunctivitis, and eczema in childhood: ISAAC Phases One and Three repeat multicountry cross-sectional surveys. Lancet 368, 733-743 (2006).
4. Ishizaka, K., Ishizaka, T. & Hornbrook, M. M. Physicochemical properties of reaginic antibody. V. Correlation of reaginic activity wth γ-E-globulin antibody. J. Immunol. 97, 840-853 (1966).
5. Eder, W., Ege, M. J. & von Mutius, E. The asthma epidemic. N. Engl. J. Med. 355, 2226-2235 (2006).
6. Hammad, H. & Lambrecht, B. N. Recent progress in the biology of airway dendritic cells and implications for understanding the regulation of asthmatic inflammation. J. Allergy Clin. Immunol. 118, 331-336 (2006).
7. Glimcher, L. H. Trawling for treasure: tales of T-bet. Nature Immunol. 8, 448-450 (2007).
8. Hammad, H. & Lambrecht, B. N. Dendritic cells and epithelial cells: linking innate and adaptive immunity in asthma. Nature Rev. Immunol. 8, 193-204 (2008).
9. von Garnier, C. et al. Allergic airways disease develops after an increase in allergen capture and processing in the airway mucosa. J. Immunol. 179, 5748-5759 (2007).
10. H2 cytokines. J. Immunol. 169, 2498-2506 (2002).
11. Romagnani, S. Regulation of the T-cell response. Clin. Exp. Allergy 36, 1357-1366 (2006).
12. Wing, K., Fehervari, Z. & Sakaguchi, S. Emerging possibilities in the development and function of regulatory T cells. Int. Immunol. 18, 991-1000 (2006).
13. Seddiki, N. et al. Expression of interleukin (IL)-2 and IL-7 receptors discriminates between human regulatory and activated T cells. J. Exp. Med. 203, 1693-1700 (2006).
14. Bacchetta, R., Gambineri, E. & Roncarolo, M. G. Role of regulatory T cells and FOXP3 in human diseases. J. Allergy Clin. Immunol. 120, 227-235 (2007).
15. Larche, M. Regulatory T cells in allergy and asthma. Chest 132, 1007-1014 (2007).
16. H17 cells: an orphan with influence. Immunol. Cell Biol. 85, 83-84 (2007).
17. Chen, Z., Tato, C. M., Muul, L., Laurence. A. & O'Shea, J. J. Distinct regulation of interleukin-17 in human T helper lymphocytes. Arthritis Rheum. 56, 2936-2946 (2007).
18. Bullens, D. M. et al. IL-17 mRNA in sputum of asthmatic patients: linking T cell driven inflammation and granulocytic influx? Respir. Res. 7, 135 (2006).
19. Dragon, S. et al. IL-17 enhances IL-1β-mediated CXCL8 release from human airway smooth muscle cells. Am. J. Physiol. Lung Cell. Mol. Physiol. 292, L1023-L1029 (2007).
20. Cockcroft, D. W., Hargreave, F. E., O'Byrne, P. M. & Boulet, L. P. Understanding allergic asthma from allergen inhalation tests. Can. Respir. J. 14, 414-418 (2007).
21. Kelly, M., Hwang, J. M. & Kubes, P. Modulating leukocyte recruitment in inflammation. J. Allergy Clin. Immunol. 120, 3-10 (2007). An important review that describes the molecular mechanisms of the leukocyte-recruitment cascade. It includes most of the important original papers in this field.
22. Palmqvist, C., Wardlaw, A. J. & Bradding, P. Chemokines and their receptors as potential targets for the treatment of asthma. Br. J. Pharmacol. 151, 725-736 (2007).
23. Pease, J. E. & Williams, T. J. The attraction of chemokines as a target for specific anti-inflammatory therapy. Br. J. Pharmacol. 147 (Suppl. 1), S212-S221 (2006).
24. Schleimer, R. P., Kato, A., Kern, R., Kuperman, D. & Avila, P. C. Epithelium: at the interface of innate and adaptive immune responses. J. Allergy Clin. Immunol. 120, 1279-1284 (2007). This review discusses recent studies that have looked at the molecular and cellular mechanisms by which epithelial cells help to shape the immune and inflammatory responses of dendritic cells, T cells and B cells, and inflammatory-cell recruitment in the context of human disease.
25. Holgate, S. T. The epithelium takes centre stage in asthma and atopic dermatitis. Trends Immunol. 28, 248-251 (2007).
26. Bucchieri, F. et al. Asthmatic bronchial epithelium is more susceptible to oxidant-induced apoptosis. Am. J. Respir. Cell Mol. Biol. 27, 179-185 (2002).
27. Davies, D. E., Wicks, J., Powell, R. M., Puddicombe, S. M. & Holgate, S. T. Airway remodeling in asthma: new insights. J. Allergy Clin. Immunol. 111, 215-225 (2003). A provocative review that discusses an alternative view of asthma pathogenesis by emphasizing the crucial role played by the airway microenvironment and by changes due to remodelling.
28. Klunker, S. et al. A second step of chemotaxis after transendothelial migration: keratinocytes undergoing apoptosis release IFN-γ-inducible protein 10, monokine induced by IFN-γ, and IFN-γ-inducible α-chemoattractant for T cell chemotaxis toward epidermis in atopic dermatitis. J. Immunol. 171, 1078-1084 (2003).
29. Illi, S. et al. Perennial allergen sensitisation early in life and chronic asthma in children: a birth cohort study. Lancet 368, 763-770 (2006). This large, prospective, multicentre study investigates the role of allergic sensitization and allergen exposure early in life and shows that sensitization to perennial allergens developing in the first 3 years of life is associated with a loss of lung function and increased the development of airway hyper-responsiveness at school age.
30. Corver, K. et al. House dust mite allergen reduction and allergy at 4 yr: follow up of the PIAMA-study. Pediatr. Allergy Immunol. 17, 329-336 (2006).
31. Woodcock, A. et al. Early life environmental control: effect on symptoms, sensitization, and lung function at age 3 years. Am. J. Respir. Crit. Care Med. 170, 433-439 (2004).
32. Arshad, S. H., Bateman, B., Sadeghnejad, A., Gant, C. & Matthews, S. M. Prevention of allergic disease during childhood by allergen avoidance: the Isle of Wight prevention study. J. Allergy Clin. Immunol. 119, 307-313 (2007).
33. Turcanu, V., Maleki, S. J. & Lack, G. Characterization of lymphocyte responses to peanuts in normal children, peanut-allergic children, and allergic children who acquired tolerance to peanuts. J. Clin. Invest. 111, 1065-1072 (2003).
34. Holt, P. G. & Sly, P. D. Prevention of allergic respiratory disease in infants: current aspects and future perspectives. Curr. Opin. Allergy Clin. Immunol. 7, 547-555 (2007).
35. Woodcock, A. et al. Control of exposure to mite allergen and allergen-impermeable bed covers for adults with asthma. N. Engl. J. Med. 349, 225-236 (2003).
36. Terreehorst, I. et al. Evaluation of impermeable covers for bedding in patients with allergic rhinitis. N. Engl. J. Med. 349, 237-246 (2003).
37. Barnes, P. J., Chung, K. F. & Page, C. P. Inflammatory mediators of asthma: an update. Pharmacol. Rev. 50, 515-596 (1998).
38. Barnes, P. J. & Adcock, I. M. Transcription factors and asthma. Eur. Respir. J. 12, 221-234 (1998).
39. Barnes, P. J. & Adcock, I. M. How do corticosteroids work in asthma? Ann. Intern. Med. 139, 359-370 (2003). This article summarizes recent developments in our understanding of the fundamental mechanisms of gene transcription, which have led to important advances in our understanding of the molecular mechanisms by which corticosteroids suppress inflammation and provide insights into why corticosteroids fail to work in patients with steroid-resistant asthma.
40. Bisgaard, H., Hermansen, M. N., Loland, L., Halkjaer, L. B. & Buchvald, F. Intermittent inhaled corticosteroids in infants with episodic wheezing. N. Engl. J. Med. 354, 1998-2005 (2006).
41. Guilbert, T. W. et al. Long-term inhaled corticosteroids in preschool children at high risk for asthma. N. Engl. J. Med. 354, 1985-1997 (2006). References 40 and 41 are large, controlled, prospective studies that provide decisive evidence that early anti-inflammatory therapy with inhaled corticosteroids in pre-school children at high risk for asthma fails to modify the natural course of the disease.
42. Harrison, T. W., Oborne, J., Newton, S. & Tattersfield, A. E. Doubling the dose of inhaled corticosteroid to prevent asthma exacerbations: randomised controlled trial. Lancet 363, 271-275 (2004).
43. Chaudhuri, R. et al. Cigarette smoking impairs the therapeutic response to oral corticosteroids in chronic asthma. Am. J. Respir. Crit. Care Med. 168, 1308-1311 (2003).
44. Palmqvist, M. et al. Inhaled dry-powder formoterol and salmeterol in asthmatic patients: onset of action, duration of effect and potency. Eur. Respir. J. 10, 2484-2489 (1997).
45. Usmani, O. S. et al. Glucocorticoid receptor nuclear translocation in airway cells after inhaled combination therapy. Am. J. Respir. Crit. Care Med. 172, 704-712 (2005).
46. Mcivor, R. A. et al. Potential masking effects of salmeterol on airway inflammation in asthma. Am. J. Respir. Crit. Care Med. 158, 924-930 (1998).
47. Del, C. A. et al. Comparative pharmacology of the H1 antihistamines. J. Invest. Allergol. Clin. Immunol. 16 (Suppl 1), 3-12 (2006).
48. 4, which provides evidence in favour of the theory that there is an additive therapeutic efficacy of antileukotrienes with inhaled corticosteroids in asthma.
49. Kemp, J. P. Recent advances in the management of asthma using leukotriene modifiers. Am. J. Respir. Med. 2, 139-156 (2003).
50. Polosa, R. Critical appraisal of antileukotriene use in asthma management. Curr. Opin. Pulm. Med. 13, 24-30 (2007).
51. Nayak, A. & Langdon, R. B. Montelukast in the treatment of allergic rhinitis: an evidence-based review. Drugs 67, 887-901 (2007).
52. Friedmann, P. S. et al. A double-blind, placebo-controlled trial of montelukast in adult atopic eczema. Clin. Exp. Allergy 37, 1536-1540 (2007).
53. Boswell-Smith, V., Cazzola, M. & Page, C. P. Are phosphodiesterase 4 inhibitors just more theophylline? J. Allergy Clin. Immunol. 117, 1237-1243 (2006).
54. Holgate, S. T. & Polosa, R. The mechanisms, diagnosis, and management of severe asthma in adults. Lancet. 368, 780-793 (2006).
55. Hijnen, D. J., Knol, E., Bruijnzeel-Koomen, C. & de Bruin-Weller, M. Cyclosporin A treatment is associated with increased serum immunoglobulin E levels in a subgroup of atopic dermatitis patients. Dermatitis 18, 163-165 (2007).
56. H2 cytokine mRNA measurement in sputum of asthma patients. Thorax 61, 202-208 (2006).
57. Howarth, P. H. et al. Tumour necrosis factor (TNFα) as a novel therapeutic target in symptomatic corticosteroid-dependent asthma. Thorax 60, 1012-1018 (2005).
58. Waserman, S., Dolovich, J., Conway, M. & Marshall, J. S. TNFα dysregulation in asthma: relationship to ongoing corticosteroid therapy. Can. Respir. J. 7, 229-237 (2000).
59. Berry, M. A. et al. Evidence of a role of tumor necrosis factor-α in refractory asthma. N. Engl. J. Med. 354, 697-708 (2006).
60. Duan, W. et al. Inhaled p38α mitogen-activated protein kinase antisense oligonucleotide attenuates asthma in mice. Am. J. Respir. Crit. Care Med. 171, 571-578 (2005).
61. Birrell, M. A. et al. IκB kinase-2-independent and - dependent inflammation in airway disease models: relevance of IKK-2 inhibition to the clinic. Mol. Pharmacol. 69, 1791-1800 (2006). This was the first study to examine the effect of an IKK2 inhibitor (TPCA-1) in well-validated models that mimic aspects of airway inflammation. TPCA-1 blocked the increase in NF-κB binding to DNA with an associated decrease in the release of inflammatory mediators and in the inflammatorycell burden in the lungs.
62. Wu, K., Bi, Y., Sun, K. & Wang, C. IL-10-producing type 1 regulatory T cells and allergy. Cell Mol. Immunol. 4, 269-275 (2007).
63. Wan, Y. Y. & Flavell, R. A. 'Yin-Yang' functions of transforming growth factor-β and T regulatory cells in immune regulation. Immunol. Rev. 220, 199-213 (2007).
64. Durham, S. R. et al. Long-term clinical efficacy of grass-pollen immunotherapy. N. Engl. J. Med. 341, 468-475 (1999).
65. Williams, A. P., Krishna, M. T. & Frew, A. J. The safety of immunotherapy. Clin. Exp. Allergy 34, 513-514 (2004).
66. Larché, M. Update on the current status of peptide immunotherapy. J. Allergy Clin. Immunol. 119, 906-909 (2007). This recent review summarizes the mechanisms by which allergen-specific immunotherapy exerts its immunological and anti-inflammatory effects. It also addresses new approaches to improve the efficacy of and decrease the incidence and severity of adverse reactions to allergen-specific immunotherapy.
67. Valenta, R. & Niederberger, V. Recombinant allergens for immunotherapy. J. Allergy Clin. Immunol. 119, 826-830 (2007).
68. Lund, L. et al. Comparison of allergenicity and immunogenicity of an intact allergen vaccine and commercially available allergoid products for birch pollen immunotherapy. Clin. Exp. Allergy 37, 564-571 (2007).
69. Wheeler, A. A novel adjuvant complex, tyrosine-MPL, for prophylactic and therapeutic vaccines. Vaccine 24 (Suppl. 2), 40-41 (2006).
70. Scholl, I., Kopp, T., Bohle, B. & Jensen-Jarolim, E. Biodegradable PLGA particles for improved systemic and mucosal treatment of Type I allergy. Immunol. Allergy Clin. North Am. 26, 349-364, ix (2006).
71. Creticos, P. S., Chen, Y. H. & Schroeder, J. T. New approaches in immunotherapy: allergen vaccination with immunostimulatory DNA. Immunol. Allergy Clin. North Am. 24, 569-581, v (2004).
72. Valovirta, E., Jacobsen, L., Ljorring, C., Koivikko, A. & Savolainen, J. Clinical efficacy and safety of sublingual immunotherapy with tree pollen extract in children. Allergy, 61, 1177-1183 (2006).
73. Ozdemir, C. et al. Efficacy of long-term sublingual immunotherapy as an adjunct to pharmacotherapy in house dust mite-allergic children with asthma. Pediatr. Allergy Immunol. 18, 508-515 (2007).
74. Pajno, G. B. Sublingual immunotherapy: the optimism and the issues. J. Allergy Clin. Immunol. 119, 796-801 (2007). A recent overview that highlights the pros and cons of sublingual immunotherapy for the treatment of patients with asthma and/or rhinitis. It also addresses new approaches to improve the treatment of patients with IgE-mediated food allergy and to modify the natural course of allergic diseases.
75. Abramson, M. J., Puy, R. M. & Weiner, J. M. Allergen immunotherapy for asthma. Cochrane Database Syst. Rev. CD001186 (2003). This meta-analysis of 75 controlled trials (including a total of 3,188 participants with asthma) indicates that there is a significant reduction in asthma symptoms and medication and an improvement in bronchial hyper-reactivity after allergen immunotherapy.
76. Lent, A. M. et al. Immunologic response to administration of standardized dog allergen extract at differing doses. J. Allergy Clin. Immunol. 118, 1249-1256 (2006).
77. Ewbank, P. A. et al. A double-blind, placebo-controlled immunotherapy dose-response study with standardized cat extract. J. Allergy Clin. Immunol. 111, 155-161 (2003).
78. Creticos, P. S. et al. Nasal challenge with ragweed pollen in hay fever patients. Effect of immunotherapy. J. Clin. Invest. 76, 2247-2253 (1985).
79. Frew, A. J., Powell, R. J., Corrigan, C. J. & Durham, S. R. Efficacy and safety of specific immunotherapy with SQ allergen extract in treatment-resistant seasonal allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 117, 319-325 (2006).
80. Des, R. A. et al. Immunotherapy with a standardized Dermatophagoides pteronyssinus extract. VI. Specific immunotherapy prevents the onset of new sensitizations in children. J. Allergy Clin. Immunol. 99, 450-453 (1997).
81. Purello-D'Ambrosio, F. et al. Prevention of new sensitizations in monosensitized subjects submitted to specific immunotherapy or not. A retrospective study. Clin. Exp. Allergy 31, 1295-1302 (2001).
82. Pajno, G. B., Barberio, G., De, L. F., Morabito, L. & Parmiani, S. Prevention of new sensitizations in asthmatic children monosensitized to house dust mite by specific immunotherapy. A six-year follow-up study. Clin. Exp. Allergy 31, 1392-1397 (2001).
83. Guerra, S., Sherrill, D. L., Martinez, F. D. & Barbee, R. A. Rhinitis as an independent risk factor for adult-onset asthma. J. Allergy Clin. Immunol. 109, 419-425 (2002).
84. Polosa, R., Al-Delaimy, W. K., Russo, C., Piccillo, G. & Sarva, M. Greater risk of incident asthma cases in adults with allergic rhinitis and effect of allergen immunotherapy: a retrospective cohort study. Respir. Res. 6, 153 (2005). This retrospective cohort study shows that allergic rhinitis is an important independent risk factor for asthma and that treatment with allergen immunotherapy was significantly and inversely related to the development of new-onset asthma in adults with allergic rhinitis.
85. Moller, C. et al. Pollen immunotherapy reduces the development of asthma in children with seasonal rhinoconjunctivitis (the PAT study). J. Allergy Clin. Immunol. 109, 251-256 (2002).
86. Niggemann, B. et al. Five-year follow-up on the PAT study: specific immunotherapy and long-term prevention of asthma in children. Allergy 61, 855-859 (2006).
87. Polosa, R. et al. Effect of immunotherapy on asthma progression, BHR and sputum eosinophils in allergic rhinitis. Allergy 59, 1224-1228 (2004).
88. Novembre, E. et al. Coseasonal sublingual immunotherapy reduces the development of asthma in children with allergic rhinoconjunctivitis. J. Allergy Clin. Immunol. 114, 851-857 (2004).
89. Gould, H. J. & Sutton, B. J. IgE in allergy and asthma today. Nature Rev. Immunol. 8, 205-217 (2008).
90. Corne, J. et al. The effect of intravenous administration of a chimeric anti-IgE antibody on serum IgE levels in atopic subjects: efficacy, safety and pharmacokinetics. J. Clin. Invest. 99, 879-887 (1997).
91. Holgate, S. T., Djukanovic, R., Casale, T. & Bousquet, J. Anti-immunoglobulin E treatment with omalizumab in allergic diseases: an update on anti-inflammatory activity and clinical efficacy. Clin. Exp. Allergy 35, 408-416 (2005).
92. Plewako, H. et al. The effect of omalizumab on nasal allergic inflammation. J. Allergy Clin. Immunol. 110, 68-71 (2002).
93. Bez, C. et al. Effect of anti-immunoglobulin E on nasal inflammation in patients with seasonal allergic rhinoconjunctivitis. Clin. Exp. Allergy 34, 1079-1085 (2004).
94. Peng, Z. et al. Novel IgE peptide-based vaccine prevents the increase of IgE and down-regulates elevated IgE in rodents. Clin. Exp. Allergy 37, 1040-1048 (2007).
95. Vernersson, M., Ledin, A., Johansson, J. & Hellman, L. Generation of therapeutic antibody responses against IgE through vaccination. FASEB J. 16, 875-877 (2002).
96. Poole, J. A., Meng, J., Reff, M., Spellman, M. C. & Rosenwasser, L. J. Anti-CD23 monoclonal antibody, lumiliximab, inhibited allergen-induced responses in antigen-presenting cells and T cells from atopic subjects. J. Allergy Clin. Immunol. 116, 780-788 (2005).
97. Edwards, A. M. & Howell, J. B. The chromones: history, chemistry and clinical development. A tribute to the work of Dr R. E. C. Altounyan. Clin. Exp. Allergy 30, 756-774 (2000).
98. Bradding, P., Walls, A. F. & Holgate, S. T. The role of the mast cell in the pathophysiology of asthma. J. Allergy Clin. Immunol. 117, 1277-1284 (2006).
99. Alton, E. W. & Norris, A. A. Chloride transport and the actions of nedocromil sodium and cromolyn sodium in asthma 1. J. Allergy Clin. Immunol. 98, S102-S105 (1996).
100. 2+ influx and degranulation in human lung mast cells. J. Allergy Clin. Immunol. 114, 66-72 (2004).
101. + channels are required for human lung mast cell migration. Thorax 61, 880-885 (2006).
102. Kraft, S. et al. Anti-CD63 antibodies suppress IgE-dependent allergic reactions in vitro and in vivo. J. Exp. Med. 201, 385-396 (2005).
103. Kraft, S. & Kinet, J. P. New developments in FcεRI regulation, function and inhibition. Nature Rev. Immunol. 7, 365-378 (2007).
104. Matsubara, S. et al. Inhibition of spleen tyrosine kinase prevents mast cell activation and airway hyperresponsiveness. Am. J. Respir. Crit. Care Med. 173, 56-63 (2006).
105. Rossi, A. B. et al. Identification of the Syk kinase inhibitor R112 by a human mast cell screen. J. Allergy Clin. Immunol. 118, 749-755 (2006). References 103-105 focus on new therapeutic approaches to inhibit mast-cell activation through the modulation of Fc-receptor signalling. The use and the potential clinical application of chimeric fusion proteins, SRC tyrosine kinases and ATP-competitive SYK inhibitors are discussed.
106. Guyer, B. J. et al. Mast cell inhibitor R112 is well tolerated and affects prostaglandin D2 but not other mediators, symptoms, or nasal volumes in a nasal challenge model of allergic rhinitis. Allergy Asthma Proc. 27, 208-213 (2006).
107. Meltzer, E. O., Berkowitz, R. B. & Grossbard, E. B. An intranasal Syk-kinase inhibitor (R112) improves the symptoms of seasonal allergic rhinitis in a park environment. J. Allergy Clin. Immunol. 115, 791-796 (2005).
108. Okayama, Y. & Kawakami, T. Development, migration, and survival of mast cells. Immunol. Res. 34, 97-115 (2006).
109. Reber, L., Da Silva, C. A. & Frossard, N. Stem cell factor and its receptor c-Kit as targets for inflammatory diseases. Eur. J. Pharmacol. 533, 327-340 (2006).
110. Berlin, A. A., Hogaboam, C. M. & Lukacs, N. W. Inhibition of SCF attenuates peribronchial remodeling in chronic cockroach allergen-induced asthma. Lab. Invest. 86, 557-565 (2006).
111. Malbec, O. & Daeron, M. The mast cell IgG receptors and their roles in tissue inflammation. Immunol. Rev. 217, 206-221 (2007).
112. Daheshia, M., Friend, D. S., Grusby, M. J., Austen, K. F. & Katz, H. R. Increased severity of local and systemic anaphylactic reactions in gp49B1-deficient mice. J. Exp. Med. 194, 227-234 (2001).
113. Strait, R. T., Morris, S. C. & Finkelman, F. D. IgG-blocking antibodies inhibit IgE-mediated anaphylaxis in vivo through both antigen interception and FcγRIIb cross-linking. J. Clin. Invest. 116, 833-841 (2006).
114. Ott, V. L., Tamir, I., Niki, M., Pandolfi, P. P. & Cambier, J. C. Downstream of kinase, p62(dok), is a mediator of FcγIIB inhibition of FcεRI signaling. J. Immunol. 168, 4430-4439 (2002).
115. Castells, M. C. et al. gp49B1-α(v)β3 interaction inhibits antigen-induced mast cell activation. Nature Immunol. 2, 436-442 (2001).
116. Allen, L. C., Kepley, C. L., Saxon, A. & Zhang, K. Modifications to an Fcγ-Fcvarε fusion protein alter its effectiveness in the inhibition of FcvarεRI-mediated functions. J. Allergy Clin. Immunol. 120, 462-468 (2007).
117. Zhu, D. et al. A chimeric human-cat fusion protein blocks cat-induced allergy. Nature Med. 11, 446-449 (2005).
118. Borish, L. C. et al. Interleukin-4 receptor in moderate atopic asthma. A phase I/II randomized, placebo-controlled trial. Am. J. Respir. Crit. Care Med. 160, 1816-1823 (1999).
119. Borish, L. C. et al. Efficacy of soluble IL-4 receptor for the treatment of adults with asthma. J. Allergy Clin. Immunol. 107, 963-970 (2001).
120. Hart, T. K. et al. Preclinical efficacy and safety of pascolizumab (SB 240683): a humanized anti-interleukin-4 antibody with therapeutic potential in asthma. Clin. Exp. Immunol. 130, 93-100 (2002).
121. Le, B. H. et al. Control of allergic reactions in mice by an active anti-murine IL-4 immunization. Vaccine 25, 7206-7216 (2007).
122. Ma, Y. et al. Novel cytokine peptide-based vaccines: an interleukin-4 vaccine suppresses airway allergic responses in mice. Allergy 62, 675-682 (2007).
123. Linhart, B. et al. Costimulation blockade inhibits allergic sensitization but does not affect established allergy in a murine model of grass pollen allergy. J. Immunol. 178, 3924-3931 (2007).
124. Wynn, T. A. IL-13 effector functions. Annu. Rev. Immunol. 21, 425-456 (2003).
125. H2-cell- mediated responses, is a potential therapeutic target for the treatment of asthma.
126. Grunig, G. et al. Requirement for IL-13 independently of IL-4 in experimental asthma. Science 282, 2261-2263 (1998).
127. Bree, A. et al. IL-13 blockade reduces lung inflammation after Ascaris suum challenge in cynomolgus monkeys. J. Allergy Clin. Immunol. 119, 1251-1257 (2007).
128. Wenzel, S., Wilbraham, D., Fuller, R., Getz, E. B. & Longphre, M. Effect of an interleukin-4 variant on late phase asthmatic response to allergen challenge in asthmatic patients: results of two phase 2a studies. Lancet 370, 1422-1431 (2007). This recent randomized controlled trial shows that nebulization of an IL-4 variant (pitrakinra) that potently inhibits the binding of IL-4 and IL-13 to IL-4Rα-containing complexes could markedly decrease the symptoms of experimental asthma.
129. Ma, Y. et al. Novel recombinant interleukin-13 peptide-based vaccine reduces airway allergic inflammatory responses in mice. Am. J. Respir. Crit. Care Med. 176, 439-445 (2007).
130. McCusker, C. T. et al. Inhibition of experimental allergic airways disease by local application of a cell-penetrating dominant-negative STAT6 peptide. J. Immunol. 179, 2556-2564 (2007).
131. Popescu, F. D. Antisense- and RNA-interference-based therapeutic strategies in allergy. J. Cell Mol. Med. 9, 840-853 (2005).
132. Menzies-Gow, A. N., Flood-Page, P. T., Robinson, D. S. & Kay, A. B. Effect of inhaled interleukin-5 on eosinophil progenitors in the bronchi and bone marrow of asthmatic and non-asthmatic volunteers. Clin. Exp. Allergy 37, 1023-1032 (2007).
133. Leckie, M. J. et al. Effects of an interleukin-5 blocking monoclonal antibody on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2144-2148 (2000).
134. Kips, J. C. et al. Effect of SCH55700, a humanized anti-human interleukin-5 antibody, in severe persistent asthma: a pilot study. Am. J. Respir. Crit. Care Med. 167, 1655-1659 (2003).
135. Flood-Page, P. et al. A study to evaluate safety and efficacy of mepolizumab in patients with moderate persistent asthma. Am. J. Respir. Crit. Care Med. 176, 1062-1071 (2007). A multicentre, randomized, double-blind, placebo-controlled study that provides conclusive evidence that treatment with an IL-5-blocking monoclonal antibody, mepolizumab, fails to give a significant clinical benefit in patients with moderate persistent asthma.
136. Flood-Page, P. T., Menzies-Gow, A. N., Kay, A. B. & Robinson, D. S. Eosinophil's role remains uncertain as anti-interleukin-5 only partially depletes numbers in asthmatic airway. Am. J. Respir. Crit. Care Med. 167, 199-204 (2003).
137. Liu, L. Y. et al. Decreased expression of membrane IL-5 receptor-α on human eosinophils: I. Loss of membrane IL-5 receptor-α on airway eosinophils and increased soluble IL-5 receptor-α in the airway after allergen challenge. J. Immunol. 169, 6452-6458 (2002).
138. Liu, L. Y. et al. Decreased expression of membrane IL-5 receptor-α on human eosinophils: II. IL-5 downmodulates its receptor via a proteinase-mediated process. J. Immunol. 169, 6459-6466 (2002).
139. Alam, R. & Busse, W. W. The eosinophil - quo vadis? J. Allergy Clin. Immunol. 113, 38-42 (2004).
140. Flood-Page, P. et al. Anti-IL-5 treatment reduces deposition of ECM proteins in the bronchial subepithelial basement membrane of mild atopic asthmatics. J. Clin. Invest. 112, 1029-1036 (2003).
141. Phipps, S., Flood-Page, P., Menzies-Gow, A., Ong, Y. E. & Kay, A. B. Intravenous anti-IL-5 monoclonal antibody reduces eosinophils and tenascin deposition in allergen-challenged human atopic skin. J. Invest. Dermatol. 122, 1406-1412 (2004).
142. Kariyawasam, H. H., Aizen, M., Barkans, J., Robinson, D. S. & Kay, A. B. Remodeling and airway hyperresponsiveness but not cellular inflammation persist after allergen challenge in asthma. Am. J. Respir. Crit. Care Med. 175, 896-904 (2007).
143. Garrett, J. K. et al. Anti-interleukin-5 (mepolizumab) therapy for hypereosinophilic syndromes. J. Allergy Clin. Immunol. 113, 115-119 (2004).
144. Stein, M. L. et al. Anti-IL-5 (mepolizumab) therapy for eosinophilic esophagitis. J. Allergy Clin. Immunol. 118, 1312-1319 (2006).
145. Oldhoff, J. M. et al. Anti-IL-5 recombinant humanized monoclonal antibody (mepolizumab) for the treatment of atopic dermatitis. Allergy 60, 693-696 (2005).
146. O'Byrne, P. et al. A single dose of MEDI-528, a monoclonal antibody against interleukin-19, is well tolerated in mild and moderate asthmatics in the phase II trial MI-CP-138. Chest 132, 478 (2007).
147. Boguniewicz, M. et al. The effects of nebulized recombinant interferon-γ in asthmatic airways. J. Allergy Clin. Immunol. 95, 133-135 (1995).
148. Reisinger, J. et al. IFNγ-enhanced allergen penetration across respiratory epithelium augments allergic inflammation. J. Allergy Clin. Immunol. 115, 973-981 (2005).
149. Simon, H. U., Seelbach, H., Ehmann, R. & Schmitz, M. Clinical and immunological effects of low-dose IFNα treatment in patients with corticosteroid-resistant asthma. Allergy 58, 1250-1255 (2003).
150. Kroegel, C. et al. Interferon-αcon1 treatment of three patients with severe glucocorticoid-dependent asthma. Effect on disease control and systemic glucocorticosteroid dose. Respiration 73, 566-570 (2006).
151. Wark, P. A. et al. Asthmatic bronchial epithelial cells have a deficient innate immune response to infection with rhinovirus. J. Exp. Med. 201, 937-947 (2005).
152. Contoli, M. et al. Role of deficient type III interferon-λ production in asthma exacerbations. Nature Med. 12, 1023-1026 (2006).
153. Holgate, S. T. Exacerbations: the asthma paradox. Am. J. Respir. Crit. Care Med. 172, 941-943 (2005).
154. Bryan, S. A. et al. Effects of recombinant human interleukin-12 on eosinophils, airway hyper-responsiveness, and the late asthmatic response. Lancet 356, 2149-2153 (2000).
155. H2 sensitization. J. Leukocyte Biol. 76, 1028-1038 (2004).
156. Grunig, G. et al. Interleukin-10 is a natural suppressor of cytokine production and inflammation in a murine model of allergic bronchopulmonary aspergillosis. J. Exp. Med. 185, 1089-1099 (1997).
157. Fu, C. L., Chuang, Y. H., Chau, L. Y. & Chiang, B. L. Effects of adenovirus-expressing IL-10 in alleviating airway inflammation in asthma. J. Gene Med. 8, 1393-1399 (2006).
158. Chernoff, A. E. et al. A randomized, controlled trial of IL-10 in humans. Inhibition of inflammatory cytokine production and immune responses. J. Immunol. 154, 5492-5499 (1995).
159. Hoffjan, S. & Stemmler, S. On the role of the epidermal differentiation complex in ichthyosis vulgaris, atopic dermatitis and psoriasis. Br. J. Dermatol. 157, 441-449 (2007).
160. Tillie-Leblond, I. et al. Keratinocyte growth factor improves alterations of lung permeability and bronchial epithelium in allergic rats. Eur. Respir. J. 30, 31-39 (2007). This original work in an animal model of chronic asthma shows that treatment with keratinocyte growth factor decreases lung permeability and airway inflammation in animals challenged with ovalbumin. The observed effects seem to be associated with restoration of epithelial integrity during chronic allergic asthma. These findings open new prospects for asthma therapies.
161. Dieckgraefe, B. K., Korzenik, J. R. & Anant, S. Growth factors as treatment options for intestinal inflammation. Ann. NY Acad. Sci. 1072, 300-306 (2006).
162. Radtke, M. L. & Kolesar, J. M. Palifermin (Kepivance) for the treatment of oral mucositis in patients with hematologic malignancies requiring hematopoietic stem cell support. J. Oncol. Pharm. Pract. 11, 121-125 (2005).
163. H2-attracting chemokines and disease severity. J. Immunol. 174, 8183-8190 (2005).
164. Satoh, M., Iida, S. & Shitara, K. Non-fucosylated therapeutic antibodies as next-generation therapeutic antibodies. Expert Opin. Biol. Ther. 6, 1161-1173 (2006).
165. Cox, G. et al. Asthma control during the year after bronchial thermoplasty N. Engl. J. Med. 356, 1327-1337 (2007).
166. Ruckert, R. et al. Blocking IL-15 prevents the induction of allergen-specific T cells and allergic inflammation in vivo. J. Immunol. 174, 5507-5515 (2005).
167. Rahman, M. S. et al. IL-17A induces eotaxin-1/CC chemokine ligand 11 expression in human airway smooth muscle cells: role of MAPK (Erk1/2, JNK and p38) pathways. J. Immunol. 177, 4064-4071 (2006).
168. Schnyder-Candrian, S. et al. Interleukin-17 is a negative regulator of established allergic asthma. J. Exp. Med. 203, 2715-2725 (2006).
169. Ballantyne, S. J. et al. Blocking IL-25 prevents airway hyperresponsiveness in allergic asthma. J. Allergy Clin. Immunol.120, 1234-1231 (2007). This paper shows that a neutralizing antibody specific for IL-25 can prevent airway hyper-responsiveness, which is an important feature of clinical asthma, and results in significantly decreased levels of IL-5 and IL-13 production, eosinophil infiltration, goblet-cell hyperplasia and serum IgE secretion in an experimental model of allergic asthma. These findings indicate that IL-25 is an important therapeutic target.
170. Hayakawa, H., Hayakawa, M., Kume, A. & Tominaga, S. Soluble ST2 blocks interleukin-33 signaling in allergic airway inflammation. J. Biol. Chem. 282, 26369-26380 (2007).
171. Sonkoly, E. et al. IL-31: a new link between T cells and pruritus in atopic skin inflammation. J. Allergy Clin. Immunol. 117, 411-417 (2006).
172. Fina, D., Fantini, M. C., Pallone, F. & Monteleone, G. Role of interleukin-21 in inflammation and allergy. Inflamm. Allergy Drug Targets 6, 63-68 (2007).
173. Liu, Y. J. Thymic stromal lymphopoietin: master switch for allergic inflammation. J. Exp. Med. 203, 269-273 (2006).
174. Matsubara, S. et al. IL-2 and IL-18 attenuation of airway hyperresponsiveness requires STAT4, IFNγ and natural killer cells. Am. J. Respir. Cell Mol. Biol. 36, 324-332 (2007).